Eslicarbazepine Acetate Tablet
Product Images NDC 43598-686

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Eslicarbazepine Acetate (NDC 43598-686). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddys Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Container1 (Container1)

Container1 (Container1)
FDA Label Image

Container2 (Container2)

Container2 (Container2)
Not available.*
FDA Label Image

Container3 (Container3)

Container3 (Container3)
FDA Label Image

Container4 (Container4)

Container4 (Container4)
FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
This text provides recommendations for dose adjustment based on factors such as age, gender, and hepatic impairment. It outlines specific instructions for different scenarios, including when dose adjustment is necessary and when it is not required. Additionally, it mentions the change due to fold change and 90% confidence interval, as well as a change relative to reference.*
FDA Label Image

Figure2 (Figure2)

Figure2 (Figure2)
FDA Label Image

Figure3a (Figure3a)

Figure3a (Figure3a)
This is a list of various anticonvulsant medications along with recommendations for adjustments based on clinical response and serum levels. It provides information on which drugs may need monitoring or dose adjustments and potential pharmacodynamic interactions.*
FDA Label Image

Figure3b (Figure3b)

Figure3b (Figure3b)
This text provides a list of drugs and their recommended adjustments. It includes information on changing doses based on observed lipid levels for simvastatin and rosuvastatin, the need for alternative birth control methods when using oral contraceptives in combination with certain medications, and the necessity of monitoring INR levels for patients on warfarin.*
FDA Label Image

Figure4 (Figure4)

Figure4 (Figure4)
FDA Label Image

Figure5 (Figure5)

Figure5 (Figure5)
The text provides information on the proportion of patients in specific percentage ranges (0 to <26%, 25 to <50%, 50 to <75%) and the corresponding reduction in seizure frequency from baseline (75-100%). This data can be used to analyze the effectiveness of a treatment or intervention on seizure reduction among patients.*
FDA Label Image

Structure (Structure)

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.